Arguments against toxic effects of chemotherapy on liver injury and regeneration in an experimental model of partial hepatectomy

Liver International

Volumn 31, Issue 3, 2011, Pages 313-321

  Rickenbacher, Andreas ^a   DeOliveira, Michelle L ^a   Tian, Yinghua ^a   Jang, Jae Hwi ^a   Riener, Marc Oliver ^a   Graf, Rolf ^a   Moritz, Wolfgang ^a   Clavien, Pierre Alain ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

5 fluorouracyl; Chemotherapy; Irinotecan; Liver regeneration; Oxaliplatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; KI 67 ANTIGEN; OXALIPLATIN; SODIUM CHLORIDE;

ADJUVANT CHEMOTHERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL; BLOOD COMPONENT; BLOOD SAMPLING; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIVER HISTOLOGY; LIVER INJURY; LIVER REGENERATION; MOUSE; NONHUMAN; PARTIAL HEPATECTOMY; STEATOSIS; SURVIVAL;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; FATTY LIVER; HEPATECTOMY; KI-67 ANTIGEN; LIVER; LIVER REGENERATION; MICE; MICE, INBRED C57BL; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 79551506570     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02446.x     Document Type: Article

References (41)

1. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-59.
2. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-18; discussion 18-21.
3. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005; 23: 8490-9.
4. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87.
5. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-82.
6. Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005; 23: 502-9.
7. Clavien PA, Oberkofler CE, Raptis DA, et al. What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology 2010; 52: 715-29.
8. Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-8.
9. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96: 1037-42.
10. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-53.
11. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7.
12. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-72.
13. Kandutsch S, Klinger M, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008; 34: 1231-6.
14. Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 2006; 243: 8-9.
15. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
16. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-6.
17. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-24.
18. Manekeller S, Seinsche A, Sioutis M, Hirner A. Extended liver resection after preoperative chemotherapy: influence on regeneration and endoplasmic reticulum stress response. Langenbecks Arch Surg 2009; 394: 681-8.
19. Jansen WJ, Zwart B, Hulscher ST, et al. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70: 335-40.
20. El-Salhy M, Hilding L, Royson H, Tjomsland V. Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. Int J Oncol 2005; 27: 687-91.
21. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997; 24: S7-2-7.
22. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995; 22: 42-6.
23. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-101.
24. Levi F. Cancer chronotherapy. J Pharm Pharmacol 1999; 51: 891-8.
25. Filipski E, Lemaigre G, Liu XH, et al. Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int 2004; 21: 613-30.
26. Li XM, Tanaka K, Sun J, et al. Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin. Br J Cancer 2005; 92: 1684-9.
27. Higgins G, Anderson R. Experimental pathology of the liver. Restoration of the liver of the white rat following partial surgical removal. Arch Path 1931; 12: 186-202.
28. Heinrich S, Jochum W, Graf R, Clavien PA. Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and liver regeneration in mice. J Hepatol 2006; 45: 35-42.
29. Koutras AK, Makatsoris T, Paliogianni F, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67: 179-82.
30. Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H. Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Ther Oncol 2009; 8: 43-51.
31. Selzner N, Selzner M, Jochum W, et al. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 2006; 44: 694-701.
32. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16.
33. Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 2010; 251: 454-60.
34. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
35. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-90.
36. Ryan P, Nanji S, Pollett A, et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010; 34: 784-91.
37. Manekeller S, Sioutis M, Hirner A, Minor T. Influence of neoadjuvant chemotherapy on liver integrity and ischemic tolerance. Z Gastroenterol 2008; 46: 17-21.
38. Zafiriou G, Grekou A, Stravoravdi P, Natsis K, Barich A. Histological and ultrastructural study of the effect of chemotherapy with 5-fluorouracil on normal liver of Wistar rats. Chemotherapy 2002; 48: 298-302.
39. Gerlach C, Sakkab DY, Scholzen T, et al. Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatology 1997; 26: 573-8.
40. Lesurtel M, Graf R, Aleil B, et al. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104-7.
41. Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs 2001; 12: 741-51.